Home > Oncology > ESMO 2019 > Gynaecological Cancers > Ovarian cancer patients benefit from combined maintenance therapy

Ovarian cancer patients benefit from combined maintenance therapy

Presented By
Prof. Isabelle Ray-Coquard (Université Claude Bernard, Lyon, France)
Conference
ESMO 2019
Trial
Phase 3, PAOLA-1/ENGOT-ov25

Prof. Isabelle Ray-Coquard (Université Claude Bernard, Lyon, France) presented the late-breaking results of the PAOLA-1/ENGOT-ov25 trial showing a benefit in progression-free survival when adding the PARP inhibitor olaparib to bevacizumab treatment, in an all-comers ovarian cancer population, irrespective of BRCA mutation [1].

PAOLA-1/ENGOT-ov25 is the first phase 3 trial to examine the efficacy and safety of a pharmacological inhibitor of the enzyme poly-ADP ribose polymerase (PARP) with bevacizumab as first-line maintenance therapy in patients in women with newly-diagnosed advanced ovarian cancer who had a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab, with and without a BRCA mutation. This international, academic-led trial enrolled 806 patients. After completing first-line chemotherapy, patients were randomly allocated ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on